论文部分内容阅读
目的观察普瑞巴林治疗神经病理性疼痛的临床疗效。方法选取2013年11月-2014年1月医院治疗的神经病理性疼痛患者66例,随机分为试验组与对照组各33例。试验组采用普瑞巴林进行治疗,对照组则采用卡马西平进行治疗,对所有患者分别在治疗前和治疗后1、2、3、4周采用疼痛视觉模拟评分(VAS)、睡眠干扰评分、汉密尔顿抑郁量表(HAMD)以及汉密尔顿焦虑量表(HAMA)进行疗效评定,并分别记录2组患者的不良反应发生情况。结果 2组患者在接受治疗后,VAS评分、睡眠干扰评分、HAMD以及HAMA均有所降低,差异具有统计学意义(P<0.05)。在治疗同时间点,试验组患者的各项评分均明显低于对照组,差异具有统计学意义(P<0.05)。治疗过程中,试验组不良反应发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论对神经病理性疼痛的治疗,采用普瑞巴林的疗效较卡马西平好,起效快、明显改善患者的疼痛、睡眠、焦虑及抑郁等症状,并发症少,值得推广。
Objective To observe the clinical efficacy of pregabalin in the treatment of neuropathic pain. Methods Sixty-six patients with neuropathic pain treated in our hospital from November 2013 to January 2014 were randomly divided into experimental group and control group with 33 cases each. The trial group was treated with pregabalin, the control group was treated with carbamazepine, all patients before treatment and 1,2,3,4 weeks after treatment with pain visual analogue scale (VAS), sleep disturbance score, Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Scale (HAMA). The incidence of adverse reactions was recorded in two groups. Results After treatment, VAS score, sleep disturbance score, HAMD and HAMA were decreased in both groups. The difference was statistically significant (P <0.05). At the same time point of treatment, the score of test group was significantly lower than that of control group, the difference was statistically significant (P <0.05). During the course of treatment, the incidence of adverse reactions in the experimental group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). Conclusions The treatment of neuropathic pain with pregabalin is more effective than carbamazepine and has rapid onset. It significantly improves the symptoms of pain, sleep, anxiety and depression in patients with less complications and is worth promoting.